The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 21, 2022

Filed:

Apr. 14, 2017
Applicant:

University of Florida Research Foundation, Inc., Gainesville, FL (US);

Inventors:

Robert A. Hromas, Gainesville, FL (US);

Elizabeth Williamson, Gainesville, FL (US);

Gayathri Srinivasan, Gainesville, FL (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 9/127 (2006.01); A61K 31/7068 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 9/127 (2013.01); A61K 31/7068 (2013.01); A61K 47/646 (2017.08); A61K 48/00 (2013.01); A61P 35/00 (2018.01); C12N 2310/141 (2013.01); C12N 2310/3513 (2013.01); C12N 2320/31 (2013.01);
Abstract

The subject invention provides a pharmaceutical composition comprising an inhibitory RNA (iRNA) that mediates sequence-specific degradation of the mRNA encoding Poly (ADP-ribose) polymerase 1 (PARP1) and methods of treating cancers by administering the pharmaceutical composition to a subject in need thereof. In one embodiment, the iRNA is miR-223, particularly, miR-223-3p or a modified miR-223-3p having substitutions and/or deletions in the sequence of miR-223-3p. In another embodiment, the cancer cells comprise one or more mutations in the genes that mediate homologous recombination DNA repair, for example, BRCA1 and/or BRCA2 genes. The cancer can be breast cancer, ovarian cancer, prostate cancer, pancreatic cancer or meso thelioma. Methods of treating cancer, for example, a cancer comprising BRCA1 and/or 2 mutations, using a combination of iRNA and a second cancer therapeutic are also provided.


Find Patent Forward Citations

Loading…